Core Viewpoint - The report from Citi indicates that CSPC Pharmaceutical Group (01093) is expected to see a resurgence in core profit growth starting in 2026, driven by its 10 existing innovative brands and over 30 innovative products set to launch by 2028 [1] Group 1 - Citi has raised the target price for CSPC from HKD 13.8 to HKD 17.4, reaffirming a strong buy rating [1] - The company completed a transaction with biopharmaceutical firm Madrigal involving the GLP-1 small molecule drug SYH2086, with an upfront payment of USD 120 million and potential milestone payments totaling USD 1.955 billion, plus sales royalties calculated as a percentage [1] - Revenue forecasts for CSPC for 2025 to 2027 have been increased by 1.6%, 14.3%, and 3% respectively, while net profit forecasts have been raised by 11.8%, 73.3%, and 11.6% to reflect completed and potential licensing projects [1]